title: New aspects of some endemic mycoses.
abstract: The treatment of mycetomas varies according to their etiological agents and the clinical state of the patient. For the treatment of eumycetomas, the azole derivatives are the drugs of choice, with itraconazole rendering better results than ketoconazole and presenting better tolerance. Actinomycetomas are treated according to different therapeutic schemes: dapsone plus sulfamethoxazol-trimethoprim (SMT), and streptomycin or amikacin or amoxicillin plus clavulanic acid. The first therapeutic scheme is very useful in the treatment of Nocardia mycetoma, while the association of amikacin plus SMT is the best treatment for those cases produced by Actinomadura madurae. Ciprofloxacin is a very useful drug for the treatment of actinomycotic mycetomas with bone lesions. Although there are several criteria for evaluating clinical outcome there is no accepted criterion of cure. During the 1990s, there was a remarkable increase in the incidence of coccidioidomycosis in California, USA. An almost ten-fold increase in the number of cases was registered during 1992 and 1993 over the usual incidence. A gradual reduction in coccidioidomycosis cases was observed in the late 1990s. This particular coccidioidomycosis outbreak took place in areas of low endemicity, as well as in those of usual high endemicity. Among the factors believed to have influenced this phenomenon were a drought followed by abundant winter/spring rainfall, increased immigration of susceptible individuals, increase in excavation/construction work and a better diagnosis of the infection, particularly in the last part of the decade. The majority of patients presented the usual clinical manifestations of symptomatic primary infection but an unusual number of cases with acute respiratory failure were observed.
authors.affiliation: Facultade de Medicina de Botucatú, Sao Paulo, Brazil.
authors.forename: R
authors.initials: R
authors.lastname: Poncio Mendes
authors.forename: R
authors.initials: R
authors.lastname: Negroni
authors.forename: A
authors.initials: A
authors.lastname: Bonifaz
authors.forename: D
authors.initials: D
authors.lastname: Pappagianis
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D002140:California / Q000453:epidemiology; D003047:Coccidioidomycosis / Q000188:drug therapy / Q000453:epidemiology*; D004196:Disease Outbreaks; D019353:Endemic Diseases; D006801:Humans; D008271:Mycetoma / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000935:Antifungal Agents